期刊
NATURE CANCER
卷 1, 期 2, 页码 197-+出版社
NATURE PORTFOLIO
DOI: 10.1038/s43018-019-0019-5
关键词
-
类别
资金
- National Institutes of Health [R01 AI127654, R01 CA203721]
- German Research Foundation [PR 1621/1-1]
- Novo Nordisk Foundation
- Lundbeck Foundation
- National Cancer Institute Cancer Center [NIH 5 P30 CA06516]
- Australian National Health and Medical Research Council Fellowships
- Medical Foundation of the University of Sydney
- University of Sydney
Primary melanomas >1 mm thickness are potentially curable by resection, but can recur metastatically. We assessed the prognostic value of the T-cell fraction (TCFr) and repertoire T-cell clonality, measured by high-throughput sequencing of the T-cell receptor beta-chain in T2-T4 primary melanomas (n = 199). TCFr accurately predicted progression-free survival and was independent of thickness, ulceration, mitotic rate and age. TCFr was second only to tumor thickness in its predictive value, using a gradient-boosted model. For accurate progression-free survival prediction, adding TCFr to tumor thickness was superior to adding any other histopathological variable. Furthermore, a TCFr >20% was protective regardless of tumor ulceration status, mitotic rate or presence of nodal disease. TCFr is a quantitative molecular assessment that predicts metastatic recurrence in primary melanoma patients whose disease has been resected surgically. The present study suggests that a successful T-cell-mediated, antitumour response can be present in primary melanomas.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据